LOGIN  |  REGISTER

MindBio Therapeutics' Booze AI Launches Ambassador Campaign. Booze AI Proves there is ZERO amount of alcohol that is safe to drink then drive

July 31, 2025 | Last Trade: C$0.01 0.005 100.00
  • Launches ambassador campaign for app.booze-ai.com 

  • Announces 30 days FREE trial. 

  • Strong drink driving deterrence messaging. 

Vancouver, British Columbia – TheNewswire - July 31, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company has launched an ambassador campaign to promote Booze AI, debuting the world’s first AI-driven, voice-activated blood alcohol concentration (BAC) estimator for use on smartphones, tablets and computers. This cutting-edge technology empowers users to monitor an estimate of their alcohol levels on the go, simply by talking to their smartphone and completing behavioural tasks, the novel software application delivering real-time insights to promote responsible drinking and prevent impaired driving.

The Booze AI App can be downloaded for FREE without a credit card for 30 days FREE use as part of the ambassador campaign.

Booze AI uses a proprietary prediction model to estimate BAC, using sophisticated machine learning techniques and processing over 41 million data points collected from human trials and passing through user’s biophysical information the app detects changes in vocal frequency, power, amplitude and cognitive performance, comparing intoxication data to sober data.  In over 20,000 tests Booze AI has been successful estimating BAC 85% of the time within a range ±0.001 of commercial breathalyser results. Users submit baseline data and follow simple voice prompts to receive BAC estimates and warnings about alcohol’s impact on driving and driving performance impairment.  The Company’s governing mantra is that there is zero amount of alcohol that is safe to drink then drive, even within the statutory and legal limits and Booze AI demonstrates the dangers of drink driving by predicting driving performance impairment, even after consuming small amounts of alcohol.

Booze AI’s proprietary BAC-Regress 0.1 model, has resolved complexities like mouth alcohol residue which is problematic for commercial alcohol breath testing and the Booze AI models, learn about users over time.  Available for download today with 30 days free trial at app.booze-ai.com Booze AI is a user-friendly tool with significant potential for intoxication detection, drink driving deterrence and harm reduction.  The Booze AI app can be easily saved to the home screen on any smartphone or tablet, for convenient use.

“Booze AI is a transformative step in alcohol safety,” said Justin Hanka, CEO of MindBio. “By merging AI innovation with a strong anti-drink-driving educational mission, we aim to save lives through informed decision-making and drink driving deterrence”.

For further information, please contact:

Justin Hanka, Chief Executive Officer

61 433140886

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Inquiries

Kristina Spionjak

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page